Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (PL)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 1, January-February, p. 95–104

Publication type: review article

Language: Polish

Krążące komórki śródbłonka w zapalnych chorobach naczyń

Circulating endothelial cells in inflammatory vascular disorders

Joanna Kluz1,, Rajmund Adamiec1,

1 Katedra i Klinika Angiologii, Nadciśnienia Tętniczego i Diabetologii AM we Wrocławiu Kolegium Karkonoskie w Jeleniej Górze

Streszczenie

Jak wykazano, w przebiegu licznych schorzeń o etiologii zapalnej dochodzi do uszkodzenia komórek śródbłonka naczyń mikrokrążenia. Zidentyfikowanie markerów postępującego uszkodzenia śródbłonka pozostaje problemem o pierwszoplanowym znaczeniu klinicznym dla diagnostyki, monitorowania aktywności i podejmowania decyzji dotyczących sposobu leczenia tych chorób. W warunkach fizjologicznych 99% komórek śródbłonka pozostaje w stanie spoczynku, co znajduje odzwierciedlenie w niskiej podstawowej liczbie krążących komórek śródbłonka (CECs – circulating endothelial cells). Wzrost liczby CECs, obserwowany w przebiegu różnych schorzeń, charakteryzujących się uszkodzeniem naczyń, wydaje się odzwierciedlać stopień uszkodzenia śródbłonka i może mieć niekorzystny wpływ na rozwój procesu chorobowego. Przedstawiamy kilka zagadnień związanych z problematyką CECs, w tym ich znaczenie jako nowego, obiecującego, nieinwazyjnego markera uszkodzenia śródbłonka w chorobach naczyń, ze szczególnym uwzględnieniem systemowych zapaleń naczyń i układowej postaci tocznia rumieniowatego. Omówimy ponadto metodę izolacji i ilościowego oznaczania tych komórek oraz ich potencjalne działanie patogenetyczne i właściwości fenotypowe, które poddane dalszej analizie mogą dostarczyć istotnych wskazówek odnośnie do patogenezy niektórych schorzeń naczyniowych.

Abstract

A variety of inflammatory disorders affect microvascular endothelial cells. From a clinical point of view, establishment of markers of ongoing endothelial injury and damage is of crucial importance to diagnose these disorders, monitor their activity and decide about treatment. In normal conditions, 99% of endothelial cells are quiescent and the physiological turnover of the endothelium is reflected by low basal levels of circulating endothelial cells (CECs). Increased number of these cells in various diseases linked with vascular injury seems to be a sign of severe vascular disturbance and may contribute adversely to the disease process. Several clinical interest of CECs will be discussed, including their relevance as a promising, non−invasive marker of endothelial injury, disease activity, severity or treatment efficacy, as well as their use in diagnostic tests, particularly in systemic vasculitides and systemic lupus erythematosus. In addition we describe the methodology of isolation of these cells, their potential pathophysiologic effects and phenotypic features which, when further assessed, may help to elucidate the pathogenesis of some vascular disorders.

Słowa kluczowe

krążące komórki śródbłonka, systemowe zapalenia naczyń, SLE

Key words

circulating endothelial cells, systemic vasculitides, SLE

References (48)

  1. Chong AY, Blann AD, Lip GYH: Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM 2003, 96, 253–267.
  2. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP: Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997, 337, 1584–1590.
  3. George F, Poncelet P, Laurent JC, Massot O, Arnoux D, Ambrosi P, Klein−Soyer C, Cazenave JP, Sampol J: Rapid isolation of human endothelial cells from whole blood using S−Endo 1 monoclonal antibody coupled to magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 1992, 67, 147–153.
  4. Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, Sampol J, Solovey A, Dignat−George F: Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005, 93, 228–235.
  5. Goon PKY, Lip GYH, Boos CJ, Stonelake PS, Blann AD: Circulating Endothelial Cells, Endothelial Progenitor Cells, and Endothelial Microparticles in Cancer. Neoplasia 2006, 8, 79–88.
  6. Makin AJ, Blann AD, Chung NAY, Silverman SH, Lip GYH: Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells: relationship with von Willebrand factor and tissue factor. Eur Heart J 2004, 25, 371–376.
  7. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat−George F: Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999, 93, 2951–2958.
  8. McClung JA, Naseer N, Saleem M, Rossi GP, Weiss MB, Abraham NG, Kappas A: Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c. Diabetologia 2005, 48, 345–350.
  9. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M: Circulating endothelial cells as markers for ANCA−associated small−vessel vasculitis. Lancet 2003, 361, 206–210.
  10. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Tokutomi T, Sekine I: Circulating endothelial cells in Kawasaki disease. Clin Exp Immunol 2003, 131, 536–540.
  11. Woywodt A, Schroeder M, Mengel M, Schwarz A, Gwinner W, Haller H, Haubitz M: Circulating endothelial cells are a novel marker of cyclosporine−induced endothelial damage. Hypertension 2003, 41, 720–723.
  12. Woywodt A, Scheer J, Hambach L, Buchholz S, Ganser A, Haller H, Hertenstein B, Haubitz M: Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem−cell transplantation. Blood 2004, 103, 3603–3605.
  13. Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J: Circulating activated endothelial cells in systemic lupus erythematosus: Further evidence for diffuse vasculopathy. Arthritis Rheum 2001, 44, 1203–1208.
  14. Haubitz M, Woywodt A: Circulating endothelial cells and vasculitis. Intern Med 2004, 43, 660–667.
  15. Camoin−Jau L, Chabrol B, Sampol J, Dignat−George F: Circulating endothelial cells in Behçet’s disease with cerebral thrombophlebitis. Thromb Haemost 2000, 83, 631–632.
  16. Del Papa N, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, Maglione W, Comina DP, Vitali C, Fantini F, Cortelezzi A: Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004, 50, 1296–1304.
  17. Mancuso P, Cassi C, Gobbi A, Capillo M, Pruneri G, Martinelli G, Bertolini F: Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003, 522, 83–97.
  18. Woywodt A, Schroeder M, Gwinner W, Mengel M, Jaeger M, Schwarz A, Haller H, Haubitz M: Elevated numbers of circulating endothelial cells in renal transplant recipients. Transplantation 2003, 76, 1–4.
  19. G e − orge F, Brouqui P, Boffa MC, Mutin M, Drancourt M, Brisson C, Raoult D, Sampol J: Demonstration of Rickettsia conorii−induced endothelial injury in vivo by measuring circulating endothelial cells, thrombomodulin and von Willebrand factor in patients with Mediterranean spotted fever. Blood 1993, 82, 2109–2116.
  20. Grefte A, Van Der Giessen M, Van Son W, The H: Circulating cytomegalovirus (CMF)−infected endothelial cells in patients with an active CMV infection. J Infect Dis 1993, 167, 270–277.
  21. Mutunga M, Fulton B, Bullock R, Batchelor A, Gascoigne A, Gillespie JI, Baudouin SV: Circulating endothelial cells in patient with septic shock. Am J Respir Crit Care Med 2001, 163, 195–200.
  22. Lefevre P, George F, Durand JM, Sampol J: Detection of circulating endothelial cells in thrombotic thrombocytopenic purpura. Thromb Haemost 1993, 69, 522.
  23. Reinders MEJ, Rabelink TJ, Briscoe DM: Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006, 17, 932–942.
  24. Woywodt A, Bahlmann FH, de Groot K, Haller H, Haubitz M: Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer. Nephrol Dial Transplant 2002, 17, 1728–1730.
  25. Boos CJ, Lip GYH, Blann AD: Circulating Endothelial Cells in Cardiovascular Disease. JACC 2006, 48, 1538–1547.
  26. Štefanec T: Endothelial apoptosis: the missing link between atherosclerosis and SLE? Blood 2004, 103, 3608–3609.
  27. Holmén C, Elsheikh E, Stenvinkel P, Rashid Qureshi A, Pettersson E, Jalkanen S, Sumitran−Holgersson S: Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in vasculitis patients with kidney involvement. J Am Soc Nephrol 2005, 16, 3110–3120.
  28. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418, 191–195.
  29. Krysko DV, Brouckaert G, Kalai M, Vandenabeele P, D’Herde K: Mechanisms of internalization of apoptotic and necrotic L929 cells by a macrophage cell line studied by electron microscopy. J Morphol 2003, 258, 336–345.
  30. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP: Sickle blood contains tissue factor−positive microparticles derived from endothelial cells and monocytes. Blood 2003, 102, 2678–2683.
  31. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, Hack CE, Sturk A: Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000, 95, 930–935.
  32. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A: Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Hypertension 2003, 41, 211–217.
  33. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275, 964–967.
  34. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, Kishore R, Zhu Y, Qin G, Silver M, Thorne T, Eaton L, Masuda H, Asahara T, Losordo DW: Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow−derived endothelial progenitor cells into sites of ischemia−induced neovascularization via endothelial nitric oxide synthase−mediated activation of matrix metalloproteinase−9. Circulation 2006, 113, 1605–1614.
  35. Wassmann S, Werner N, Czech T, Nickenig G: Improvement of Endothelial Function by Systemic Transfusion of Vascular Progenitor Cells. Circ Res 2006, 99, E74–E83.
  36. Burger PE, Coetzee S, McKeehan WL, Kan M, Cook P, Fan Y, Suda T, Hebbel RP, Novitzky N, MullerWA, Wilson EL: Fibroblast growth factor receptor−1 is expressed by endothelial progenitor cells. Blood 2002, 100, 3527–3535.
  37. Gehling UM, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B, Hossfeld DK, Fiedler W: In vitro differentiation of endothelial cells from AC133−positive progenitor cells. Blood 2000, 95, 3106–3112.
  38. Peichev M, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Raffi S: Expression of VEGFR−2 and AC133 by circulating human CD34(+) cells identifies population of functional endothelial precursors. Blood 2000, 95, 952–958.
  39. Leor J, Marber M: Endothelial Progenitors: A New Tower of Babel?. JACC 2006, 48, 1588–1590.
  40. Fadini GP, Coracina A, Baesso I, Agostini C, Tiengo A, Avogaro A, Vigili de Kreutzenberg S: Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle−aged general population. Stroke 2006, 37, 2277–2282.
  41. Sesin CA, Yin X, Esmon CT, Buyon JP, Clancy RM: Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence. Kidney International 2005, 68, 110–120. Krążące komórki śródbłonka w zapalnych chorobach naczyń 103
  42. Woywodt A, Goldberg C, Scheer J, Regelsberger H, Haller H, Haubitz M: An improved assay for enumeration of circulating endothelial cells. Ann Hematol 2004, 83, 491–494.
  43. Gorman C, Isenberg D: Atherosclerosis and lupus. Rheumatology 2004, 43, 943–945.
  44. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349, 2399–406.
  45. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat−George F: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999, 104, 93–102.
  46. Tricot O, Mallat Z, Heymes C, Belmin J, Leseche G, Tedgui A: Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation 2000, 101, 2450–2453.
  47. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune WJ, Kaplan MJ: Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004, 103, 3677–3683.
  48. Dang A, Wang B, Li W, Zhang P, Liu G, Zheng D, Ruan Y, Liu L: Plasma endothelin−1 levels and circulating endothelial cells in patients with aortoarteritis. Hypertens Res 2000, 23, 541–544.
© Wroclaw Medical University